Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2011-06-21

FDA Approved: LAMICTAL XR — Supplemental Application (GlaxoSmithKline LLC)

View source ↗

Summary

FDA approved a supplemental application for Lamictal XR (lamotrigine) from GlaxoSmithKline LLC. The approval updates the labeling/indications for Lamictal XR.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LAMICTAL XR (lamotrigine)

Snippet

SUPPL AP for LAMICTAL XR (LAMOTRIGINE)